Recently, an alternative strategy inhibiting tumour neoangiogenesis using bevacizumab, a humanised monoclonal antibody raised against vascular endothelial growth factor A (VEGF-A), showed no significant improvement on patient survival (Chinot et al., 2014; Gilbert et al., 2014; Kim et al., 2018), indicating the need for improved therapeutics. This evidence concerns the gene VEGFA and neoplasm.